In this MEDtalk Peter Schmid present updated data for overall survival from Impassion 130-study - a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer.   This 2nd IMpassion130 interim OS analysis confirming clinically meaningful OS benefit of this treatment combination. 

Progression-free and overall survival were significantly improved with first line treatment with pertuzumab, trastuzumab, and docetaxel in 808 pts with HER2-positive metastatic breast cancer.  OS was increased by an unprecedented 15.7 month. In this MEDtalk Sandra M. Swain present the end-of-study analysis with a median follow-up of 99 month (max 120 mo). 

The 2010 Affordable Care Act, ACA, expanded access to insurance and care for many Americans. In this MEdtalks Anna Jo Smith evaluate the impact of the ACA on stage at diagnosis and time to treatment for women with ovarian cancer.   

In this MEDtalk Kamal Chamoun explain, why nsurance type and regional income are associated with Multiple Myeloma survival. This may be related to affordability of oral antineoplastic medications. Prices have been rapidly escalating and there are well described issues with affordability.   

The Phase III MONALEESA-7 study demonstrated that the addition of ribociclib to a nonsteroidal aromatase inhibitor or tamoxifen + goserelin significantly extended progression-free survival. In this MEDtalk Yen-Shen Lu explain the effect across gene expression subgroups 

Locally advanced or metastatic urothelial cancer remains a lethal disease with limited treatment options for patients who progress on or after platinum and/or checkpoint inhibitor (CPI).   In this MEDtalk Daniel Peter Petrylak present a new streatment of urothelial cancer  Enfortumab vedotin (EV) - an antibody-drugconjugate targeting Nectin-4, which is highly expressed in UC. This study demonstrate the fact, that Enfortumab vedotin have a therapy that can help people who don’t benefit from checkpoint inhibitors.  

#Seneste udgivelse


Nr. 2 • april 2020
10. Årgang
  • Overvægt øger risikoen for flere kræftsygdomme
  • Kol og Lungecancer
  • Prostatacancer og ostoporose

ASCO på twitter